Guangzhou Zhongzhinan Supply Chain Co.,Ltd. , https://www.gzzhongzhinan.com
Transgene said in a statement issued on Tuesday that in the development of this anti-cancer agent, the company has followed Jennerex's investment in the principle of fairness and balance, and that the latter will be phased according to the progress of drug development. The total amount of royalties will reach US$116 million and will also receive double-digit sales. Jennerex has the option to jointly promote products and share profits in the five major European markets. In addition, the company can also maintain its licensing rights in the United States.
Early clinical trials have shown that several tumor cells, including liver, colon, kidney, lung, and melanoma, respond to JX-594.
The two companies stated that they plan to conduct two clinical trials to further observe the efficacy of JX-594. One of the major 2b/3 clinical trials will focus on the efficacy of JX-594 in the treatment of liver cancer, and another phase 2 clinical trial. The effect of drugs for colorectal cancer will be observed. This formulation is expected to be launched in Europe in 2015 and its sales are expected to exceed $1 billion.
According to foreign media reports, the US anticancer drug research and development company Jennerex is working with the French biological preparation group Transgene to jointly develop a virus that can fight cancer. This virus is temporarily named as JX-594, which can target the role of cancer The cells kill them.